EGFR S768N

CI-VAR-00004119Explore in graph →ENST00000275493.2:c.2303G>ACIViC 1443 rs121913465

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma2
EGFR S768N	Erlotinib	Predictive	B	Supports Resistance	—	submitted	EID4271 The S768N mutation was first reported in a cohort of African American patients with non-small cell lung cancer (NSCLC). Classical EGFR mutations such as the L858R mutation and exon 19 deletions, foun… (full text at CIViC) PMID 19786660 · Leidner et al., 2009 · Open in CIViC	civic
EGFR S768N	Erlotinib	Predictive	D	Supports Resistance	—	submitted	EID4272 Cells expressing EGFR harboring the S768N mutation were resistant to erlotinib treatment of up to 3uM, as measured using an in vitro fibril formation assay. This contrasts with cells expressing the L8… (full text at CIViC) PMID 21132006 · Harada et al., 2011 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.